Clinical Trial Update: A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma [Phase 1]

View source ↗

Summary

Phase 1 pilot study update of pembrolizumab in surgically accessible recurrent/progressive glioblastoma. The study investigates early immunologic pharmacodynami…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Brain Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-11-26